Ipsen S.A. Confirms Financial Guidance for the Full-Year 2026 Apr 25
Ipsen Receives European Union Approval for Ojemda as Targeted Therapy in Relapsed or Refractory Pediatric Low-Grade Glioma Apr 24
Ipsen S.A., Annual General Meeting, May 13, 2026 Apr 07
Ipsen Showcases Transformative Potential of Early Immuno-Oncology Pipeline At AACR Mar 18
Ipsen Announces Executive Changes Mar 13
Ipsen Voluntarily Withdraws Tazverik in Follicular Lymphoma and Epithelioid Sarcoma Mar 10
Ipsen S.A. Provides Earnings Guidance for the Full Year 2026 Feb 12
Ipsen Nominates Peter Guenter to its Board of Directors, Effective January 28, 2026 Jan 29
Ipsen Announces Executive Changes Jan 27
Ipsen Announces Pivotal Phase II FALKON Trial Do Not Meet Its Primary Endpoint of Reducing New Heterotopic Ossification in Adults and Children Living with Fibrodysplasia Ossificans Progressiva Dec 20
Ipsen S.A. (ENXTPA:IPN) completed the acquisition of ImCheck Therapeutics SAS from Kurma Partners SA, Gimv NV (ENXTBR:GIMB) and others. Dec 16
Ipsen Announces Demise of Board Member Henri Beaufour on November 28, 2025 Dec 01
Ipsen Announces That Japan's Ministry of Health, Labour and Welfare Grants Regulatory Approval for Bylvay®? (Odevixibat) for the Treatment of Pruritus Associated with Progressive Familial Intrahepatic Cholestasis Sep 20
Medison and Ipsen Announces Health Canada Approves Bylvay™? (odevixibat) for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Sep 10
Ipsen S.A. Revises Earnings Guidance for the Year 2025 Jul 31
Exelixis, Inc. Partner Ipsen Receives European Commission Approval for CABOMETYX®? (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors Jul 25
Ipsen S.A. Announces New Appointments to Its Executive Committee Jul 23
Ipsen to Present Data from the Late-Breaking Elafibranor in the Investigational Phase II ELMWOOD Study at the European Association for the Study of the Liver (EASL) Congress Apr 24
Ipsen S.A. Confirms Guidance for the Full-Year 2025 Apr 17
Ipsen S.A. Provides Earnings Guidance for the Year 2025 Feb 15
Ipsen S.A., Annual General Meeting, May 21, 2025 Feb 14
Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis Sep 16
Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases Jul 26
Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024 Jul 25
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis Jun 13
Ipsen S.A. Approves Dividend, Payable on 3 June 2024 May 29
Ipsen Announces Executive Changes May 03
Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA Feb 15
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024 Jan 23
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC Dec 08
Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial Nov 14
Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024 Oct 28
Ipsen S.A. Confirms Sales Guidance for the Fiscal Year 2023 Oct 27
Ipsen S.A., Annual General Meeting, May 28, 2024 Oct 26
IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen Aug 22
Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome Jul 23
Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP Jul 22
Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease Jul 01
Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Jun 15
Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome Jun 14
Ipsen to Present New Data Jun 12
Ipsen S.A. Approves Dividend, Payable on 6 June 2023 Jun 01
Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023 May 11
Ipsen S.A. Provides Earnings Guidance for the Full Year 2023 Feb 09
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U Jan 27
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI Jan 21
Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023 Oct 26